🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "huge turning point" in the battle against superbug strains of the pathogen, according to scientists.

An International Challenge

Gonorrhoea infections are on the rise globally, with figures suggesting over 82 million instances per year. Particularly high rates are observed in the African continent and countries within the WHO's designated area, which includes Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an important and timely development in the reality of growing infection rates, escalating drug resistance and the extremely scarce treatment choices presently on offer.”

Public health authorities are deeply concerned about the rise in drug-resistant strains. The World Health Organization has classified it as a "high-priority threat". Ongoing monitoring found that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Therapies Secure Approval

One new antibiotic, alternatively called a brand name, was authorized by the American regulatory agency in December for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists anticipate that targeted use of this new drug will help delay the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GSK, also received approval in close succession. This treatment, which is additionally indicated for UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin was the result of a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to see it through.

“This milestone signifies a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Testing Outcomes and Global Access

As per findings released by a prominent scientific publication, zoliflodacin successfully treated more than 90% of uncomplicated infections. This places it at an similar efficacy with the typical regimen, which combines two antibiotics. The research included over 900 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the rights to license and sell the drug in a wide range of low-income and middle-income countries.

Medical professionals on the front lines have shared positive views. Access to a easy-to-administer therapy such as this is hailed as a "game-changer" for managing the epidemic. This is viewed as essential to alleviate the strain of the infection for patients and to prevent the spread of extremely resistant gonorrhoea around the world.